UK cost agency backs Roche leukemia drug in change of tack

December 2, 2014 12:02 AM

12 0

LONDON (Reuters) - Roche's new leukemia drug Gazyvaro has won the backing of Britain's healthcare cost-effectiveness agency NICE following a change of heart after an initial rejection two months ago.

The National Institute for Health and Care Excellence (NICE) said on Tuesday it had decided to recommend use of the drug on the state health service after Roche offered a discount and submitted revised cost-effectiveness analyses.

Also read: Palestinian president in hospital for minor ear procedure

Read more

To category page